Filing Flows › C4 Therapeutics (CCCC) › Q4 2025
C4 Therapeutics (CCCC) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 26, 2026
C4 Therapeutics (CCCC) reported revenue of $11.0M for the fourth quarter 2025 (Q4 2025), +113% from a year earlier and -2% from the quarter before. Operating margin was -210.1%, net loss $20.5M (186.0% of revenue).
C4 Therapeutics, Q4 2025: revenue $11.0M (+113% year over year), operating margin -210.1%, net loss $20.5M, operating cash flow −$22.1M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $11.0M | -2% | +113% |
| Operating profit | −$23.1M | — | — |
| Net earnings | −$20.5M | — | — |
| Operating cash flow | −$22.1M | — | — |
What changed
Revenue was $11.0M in Q4 2025, up 113% year over year and down 2% from the previous quarter.
Operating costs exceeded revenue by $23.1M, an operating margin of -210.1%. Total costs fell 20% while revenue rose 113%. The quarter ended with a net loss of $20.5M, narrower than the previous quarter's $32.2M loss.
Operating cash flow was −$22.1M. Non-cash charges added back $377K of depreciation and $4.0M of share-based compensation. Working capital and other items used $6.0M. Capital expenditures of $11K exceeded it, leaving free cash flow of −$22.2M.
Questions
What was C4 Therapeutics' revenue in the fourth quarter 2025?
C4 Therapeutics (CCCC) reported revenue of $11.0M for the fourth quarter 2025 (Q4 2025), +113% from a year earlier and -2% from the quarter before.
Was C4 Therapeutics profitable in the fourth quarter 2025?
Operating loss was $23.1M (-210.1% of revenue) and net loss $20.5M.
Source: C4 Therapeutics 10-K on SEC EDGAR.